Study: Brain Pacemakers May Treat Depression

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

Gift this article

LAURAN NEERGAARD

Published: May 26, 2008, 10:32 PM ET
Updated:Feb 10, 2022, 01:36 PM ET

WASHINGTON — It’s a new frontier for psychiatric illness: Brain pacemakers that promise to act as antidepressants by changing how patients’ nerve circuitry fires.

Study: Brain Pacemakers May Treat Depression

Study: Brain Pacemakers May Treat Depression

More from the New York Sun

Dublin Sets Planning for United Ireland in Motion on an Island Haunted by the ‘Troubles’

Albania’s Capital Burns Over a Kushner Resort as Prime Minister Rama Blames a ‘Hybrid War’

Syria Shuts Women Out of Military Colleges and Paints Headscarves Into Schoolbooks

Why Putin Has So Much Room To Maneuver in War Against Ukraine

Italian Courts Undermine Giorgia Meloni’s Efforts To Uphold Law and Order Amid Spate of Riots

Congo’s Former President, Sentenced to Death for Backing Rebels, Now Leads Them Toward Key Border City

Afghan Women Can’t Become Doctors and Male Doctors Are Told Not To Treat Them

Personalized Cancer Vaccine Cuts Melanoma Relapse Risk by 42 Percent in Landmark Trial

More from the New York Sun

Dublin Sets Planning for United Ireland in Motion on an Island Haunted by the ‘Troubles’

Albania’s Capital Burns Over a Kushner Resort as Prime Minister Rama Blames a ‘Hybrid War’

Syria Shuts Women Out of Military Colleges and Paints Headscarves Into Schoolbooks

Why Putin Has So Much Room To Maneuver in War Against Ukraine

Italian Courts Undermine Giorgia Meloni’s Efforts To Uphold Law and Order Amid Spate of Riots

Congo’s Former President, Sentenced to Death for Backing Rebels, Now Leads Them Toward Key Border City

Afghan Women Can’t Become Doctors and Male Doctors Are Told Not To Treat Them

Personalized Cancer Vaccine Cuts Melanoma Relapse Risk by 42 Percent in Landmark Trial